文献速递妇科产科

心脏代谢状态对口服绝经激素治疗心血管效应的影响

Influence of Cardiometabolic Status on Cardiovascular Effects of Oral Menopausal Hormone Therapy.
PubMed 文献 · Obstet Gynecol · 2026-07-24

该研究为两项双盲安慰剂对照随机试验的二次分析,纳入50-79岁绝经后女性,评估心脏代谢状态对口服结合马雌激素(CEE)或CEE联合醋酸甲羟孕酮(MPA)的心血管结局风险的影响。主要结局为冠心病(CHD)。结果显示,在未治疗且低密度脂蛋白(LDL)胆固醇≥190 mg/dL者中,CEE+MPA使CHD风险增加超过一倍(HR 2.77;95%CI 1.42-5.40;而经治疗的高脂血症患者风险未增加。血脂评估可能有助于选择CEE或CEE+MPA治疗对象。

要点

  • 未治疗且LDL≥190 mg/dL者使用CEE+MPA,CHD风险增加超过一倍(HR 2.77)。
  • 经治疗的高脂血症患者使用CEE或CEE+MPA未增加CHD风险。
  • 血脂评估可能有助于选择适合CEE或CEE+MPA治疗的患者。

核心结论

  • 使用CEE+MPA时基线LDL胆固醇较高,或使用CEE时HDL胆固醇较低,均与所有年龄组CHD风险增加相关。
  • 既往接受过高脂血症治疗的患者使用CEE+MPA或CEE相比安慰剂未显示CHD风险增加。
  • 血脂评估可能有助于选择CEE或CEE+MPA治疗的患者。

研究设计与样本

  • 两项双盲安慰剂对照随机对照试验的二次分析。
  • CEE单药试验纳入10,739名已行子宫切除术的参与者。
  • CEE+MPA试验纳入16,608名子宫完整的参与者。
  • 研究对象为50-79岁绝经后女性,干预为口服CEE 0.625 mg/d或CEE联合MPA 2.5 mg/d,对照为安慰剂。

主要发现

  • CEE单药试验中,LDL/HDL比值升高呈现相似但非显著的风险模式。
  • 血压、血糖、甘油三酯或代谢综合征未改变CEE或CEE+MPA相关的CHD风险。

关键数值与推荐

  • 未治疗且LDL<130 mg/dL者使用CEE+MPA的CHD HR 0.59(95%CI 0.31-1.10)。

临床怎么用

  • 在启动CEE或CEE+MPA治疗前评估血脂谱,尤其关注LDL和HDL水平。
  • 对未治疗且LDL胆固醇≥190 mg/dL的患者,使用CEE+MPA需警惕CHD风险增加。
  • 对经治疗的高脂血症患者,CEE或CEE+MPA未显示增加CHD风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess risk of adverse cardiovascular outcomes from menopausal hormone therapy (MHT) by cardiometabolic status. METHODS: Secondary analysis of two double-blind placebo-controlled randomized controlled trials of conjugated equine estrogens ([CEE] 0.625 mg/d) or CEE with medroxyprogesterone acetate ([MPA] 2.5 mg/d) compared with placebo in postmenopausal women aged 50-79 years. The primary outcome was coronary heart disease ([CHD], nonfatal myocardial infarction or CHD death). Cardiometabolic status was evaluated by lipid profile, blood pressure, blood glucose, and presence of metabolic syndrome (MetS). RESULTS: The CEE-alone trial enrolled 10,739 participants who had undergone hysterectomy, and the CEE+MPA trial enrolled 16,608 participants with an intact uterus. Randomization to oral MHT did not increase CHD risk in participants with a history of treated hyperlipidemia or in untreated participants with favorable lipid profiles, but risk increased in those with unfavorable lipid profiles. In the CEE+MPA trial, the CHD risk in untreated participants with normal low-density lipoprotein (LDL) cholesterol levels (less than 130 mg/dL) was similar to that of placebo-treated participants (hazard ratio [HR] 0.59; 95% CI, 0.31-1.10); however, for elevated LDL 190 mg/dL or higher, the risks were more than doubled (HR 2.77; 95% CI, 1.42-5.40; P -trend=.002). Risk of CHD increased with higher LDL/high-density lipoprotein (HDL) ratios (ratio less than 2.5: HR 0.73; 95% CI, 0.39-1.37 vs ratio 4 or higher: HR 1.76; 95% CI, 1.08-2.88 ( P -trend=.008). Similar but nonsignificant risk patterns risk by increasing level of LDL/HDL ratio were seen for CEE-alone compared with placebo. Participants with HDL cholesterol levels 60 mg/dL or greater (vs less than 50 mg/dL) appeared to be at somewhat lower risk (HRs 0.68 and 1.24, P -trend=.02). The patterns for effect modification on CHD risk by untreated LDL cholesterol levels within 10-year age groups (50-59, 60-69, and 70-79 years) were consistent with the overall results in both trials. Blood pressure, blood glucose, triglycerides, or MetS did not modify CHD risk due to CEE or CEE+MPA. CONCLUSION: Higher baseline levels of LDL cholesterol when using CEE+MPA or lower levels of HDL cholesterol when using CEE resulted in an increased risk for CHD across all age groups. Prior treatment of hyperlipidemia demonstrated no increased risk of CHD in patients treated with CEE+MPA or CEE compared with those receiving placebo. Assessment of blood lipids could assist with selection of patients for treatment with CEE of CEE+MPA. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov , NCT0000611.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Rossouw JE, Aragaki AK, Manson JE, et al. Influence of Cardiometabolic Status on Cardiovascular Effects of Oral Menopausal Hormone Therapy. Obstet Gynecol. 2026. PMID: 42492078. doi:10.1097/AOG.0000000000006381

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。